Related Experiment Video
Updated: Feb 12, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Real World Outcomes of Left Atrial Appendage Occlusion
Apostolos Tzikas1, Darren Mylotte2, Martin Bergmann3
1AHEPA University Hospital, Thessaloniki, Greece.
Insights
Percutaneous left atrial appendage occlusion (LAAO) offers a stroke prevention alternative for non-valvular atrial fibrillation (AF) patients. Real-world data suggests LAAO is effective in patients ineligible for oral anticoagulation therapy, but requires further randomized trial confirmation.
Area of Science:
- Cardiology
- Medical Devices
- Stroke Prevention
Background:
- Atrial fibrillation (AF) increases stroke risk, particularly in patients ineligible for oral anticoagulation (OAC).
- Percutaneous left atrial appendage occlusion (LAAO) is an emerging device-based therapy for stroke risk reduction in AF.
- The Watchman device is FDA-approved for LAAO in OAC-eligible patients based on clinical trials.
Purpose of the Study:
- To evaluate the efficacy and safety of LAAO in patients with non-valvular AF who are ineligible for OAC therapy.
- To assess the real-world clinical outcomes of LAAO in this high-risk patient population.
Main Methods:
- Review of observational studies and real-world clinical data on LAAO in OAC-ineligible patients.
- Analysis of clinical outcomes, including stroke prevention and safety, in patients undergoing LAAO.
Main Results:
- Observational studies indicate favorable clinical outcomes for LAAO in OAC-ineligible patients.
- LAAO provides a viable treatment option for non-valvular AF patients with limited therapeutic choices.
Conclusions:
- LAAO demonstrates promising results for stroke prevention in OAC-ineligible AF patients.
- Randomized clinical trials are necessary to confirm these findings and establish LAAO as a standard of care in this population.
Abstract:
Percutaneous left atrial appendage occlusion (LAAO) is a device-based therapy for the prevention of stroke in patients with non-valvular atrial fibrillation (AF). Recently, the Watchman device (Boston Scientific, St Paul, MN, US) was approved in the US by the Food and Drug Administration (FDA) based on the results of two randomised clinical trials that evaluated LAAO in patients eligible for oral anticoagulation (OAC) therapy. However, in real-word clinical practice LAAO is typically offered to patients ineligible for OAC therapy, as they appear to have limited treatment options and consequently worse prognosis. Although LAAO has shown favourable clinical outcomes in OAC-ineligible patients in single or multicentre observational studies, these results need to be confirmed in randomised clinical trials.
Related Concept Videos
Surface Appendages of Archaea
Predicting Reaction Outcomes
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
Guidelines for Writing Outcome
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
Real Number System
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

